| Literature DB >> 23283741 |
Wioletta Adamus-Bialek1, Elzbieta Zajac, Pawel Parniewski, Wieslaw Kaca.
Abstract
Escherichia coli and Proteus mirabilis are important urinary tract pathogens. The constant increase in the antibiotic resistance of clinical bacterial strains has become an important clinical problem. The aim of this study was to compare the antibiotic resistance of 141 clinical (Sweden and Poland) and 42 laboratory (Czech Republic) P. mirabilis strains and 129 clinical (Poland) uropathogenic E. coli strains. The proportion of unique versus diverse patterns in Swedish clinical and laboratory P. mirabilis strain collections was comparable. Notably, a similar proportion of unique versus diverse patterns was observed in Polish clinical P. mirabilis and E. coli strain collections. Mathematical models of the antibiotic resistance of E. coli and P. mirabilis strains based on Kohonen networks and association analysis are presented. In contrast to the three clinical strain collections, which revealed complex associations with the antibiotics tested, laboratory P. mirabilis strains provided simple antibiotic association diagrams. The monitoring of antibiotic resistance patterns of clinical E. coli and P. mirabilis strains plays an important role in the treatment procedures for urinary tract infections and is important in the context of the spreading drug resistance in uropathogenic strain populations. The adaptability and flexibility of the genomes of E. coli and P. mirabilis strains are discussed.Entities:
Mesh:
Year: 2013 PMID: 23283741 PMCID: PMC3594826 DOI: 10.1007/s11033-012-2420-3
Source DB: PubMed Journal: Mol Biol Rep ISSN: 0301-4851 Impact factor: 2.316
List of antibiotics used in the study
| Antibiotics used against | Antibiotics by class | |
|---|---|---|
|
|
| |
| I. β-lactam antibiotics | ||
| Amoxicillin (A) | Carbenicillin (PY) | Penicillins |
| Piperacillin (PIP) | Ampicillin (AP) | |
| Amoxicillin/Clavulanate (AUG) | ||
| Cefalotin (1st G) (CF) | Cephalosporins | |
| Cefoxitin (2nd G) (CFX) | Cefuroxime (2nd G) (CXM) | |
| Cefotaxime (3rd G) (CFT) | ||
| Ceftazidime (3rd G) (CFZ) | ||
| Imipenem (IMI) | Carbapenems | |
| Aztreonam (ATM) | Monobactams | |
| Amikacin (AK) | II. Aminoglycosides | |
| Tobramycin (TB) | ||
| Gentamicin (Gm) | ||
| Netilmicin (NT) | ||
| Nalidixic acid (Na) | III. Quinolones | |
| Norfloxacin (NOR) | ||
| Ciprofloxacin (CIP) | ||
| Ofloxacin (OFX) | ||
| Tetracycline (T) | IV. Tetracyclines | |
| Polymyxin B (PB) | V. Polypeptides | |
Colistin (Polymyxin E) (CO) | ||
| Nitrofurantoin (NI) | VI. Nitrofurans | |
| Cotrimoxazole (TS) | VII. Sulfonamides | |
| Fosfomycin (F) | VIII. Folic acid derivatives | |
Comparison of antibiotic resistance patterns of E. coli and P. mirabilis collections
| Strain collections | Antimicrobial resistance patterns | |
|---|---|---|
| No. of unique patterns | No. of diverse patterns | |
|
| 15 | 36 |
| 99 Swedish clinical strains | ||
|
| 6 | 9 |
| 42 Czech laboratory strains | ||
|
| 23 | 29 |
| 44 Polish clinical strains | ||
|
| 63 | 76 |
Number (percentage) of bacterial strains resistant to the antibiotics used
| Antibiotics | No. (%) of resistant strains | |||
|---|---|---|---|---|
|
|
| |||
| Laboratory | Swedish | Polish | ||
| AUG | 0 | 2 (2.0) | 5 (12.0) | 8 (6.0) |
| A | – | – | – |
|
| PIP | – | – | – | 27 (21.0) |
| PY | 0 | 13 (13.0) | 19 (44.0) | – |
| AP | 2 (9.0) | 15 (15.0) |
| – |
| CF | – | – | – | 38 (30.0) |
| CFX | – | – | – | 12 (9.0) |
| CXM | 2 (9.0) | 3 (3.0) |
| – |
| CFT | – | – | – | 7 (5.5) |
| CFZ | – | – | – | 8 (6.0) |
| IMI | 0 | 0 |
| 0 |
| ATM | 0 | 0 |
| – |
| AK | 0 | 0 | 10 (23.0) | 1 (0.7) |
| TB | – | – | – | 12 (9.0) |
| Gm | – | – | – | 20 (16.0) |
| NT | – | – | – | 4 (3.0) |
| Na | – | – | – |
|
| NOR | 0 | 3 (3.0) | 14 (32.0) | 38 (30.0) |
| CIP | 0 | 3 (3.0) | 12 (28.0) | 38 (30.0) |
| OFX | 0 | 2 (2.0) | 18 (42.0) | – |
| T |
|
|
| – |
| PB |
|
|
| – |
| CO |
|
|
| – |
| NI |
|
|
| 24 (19.0) |
| TS | 0 | 19 (19.0) | 18 (42.0) | 42 (33.0) |
| F | – | – | – | 2 (1.0) |
Antibiotics: AUG amoxicillin/clavulanate, A amoxicillin, PIP piperacillin, PY carbenicillin, AP ampicillin, CF cefalotin, CFX cefoxitin, CXM cefuroxime, CFT cefotaxime, CFZ ceftazidime, IMI imipenem, ATM aztreonam, AK amikacin, TB tobramycin, Gm gentamicin, NT netilmicin, Na nalidixic acid, NOR norfloxacin, CIP ciprofloxacin, OFX ofloxacin, T tetracycline, PB polymyxin B, CO colistin sulfate, NI nitrofurantoin, TS cotrimoxazole, F fosfomycin; bold over 45 % of resistant strains;- not studied
Fig. 1Kohonen map of drug resistance patterns of the P. mirabilis laboratory strain collection
Fig. 2Kohonen map of drug resistance patterns of the P. mirabilis swedish strain collection
Fig. 3Kohonen map of drug resistance patterns of the P. mirabilis polish strain collection
Fig. 4Kohonen map of drug resistance patterns of the E. coli polish strain collection